ESC 365 - Q&A.

Open Access

Q&A.

Session: A Changing Paradigm: Defining the Future Role of SGLT-2 Inhibitors

Topic: Chronic Heart Failure

Speaker: Professor A. Coats (Coventry, GB) Professor B. Bozkurt (Houston, US) Professor C. Lam (Singapore, SG)

Organised by Radcliffe Medical Education - Supported by an unrestricted educational grant from the Boehringer Ingelheim & Lilly Alliance

Event: ESC Congress 2021 - The Digital Experience

Congress Presentation

About the speakers

Professor Andrew Coats

University of Warwick, Coventry (United Kingdom of Great Britain & Northern Ireland)

109 presentations

19 followers

Professor Biykem Bozkurt

Baylor College of Medicine, Houston (United States of America)

20 presentations

2 followers

Professor Carolyn Sp Lam

National Heart Centre Singapore, Singapore (Singapore)

136 presentations

43 followers

5 more presentations in this session

SGLT-2 Inhibitors in Heart Failure: Where are we now and where are we heading?

Speaker: Professor A. Coats (Coventry, GB)

Access

Summary of how the Tx paradigm for HF has changed.

Speaker: Professor B. Bozkurt (Houston, US)

Access

Unanswered Questions.

Speaker: Professor A. Coats (Coventry, GB) Professor B. Bozkurt (Houston, US) Professor C. Lam (Singapore, SG)

Access

Best practice of SGLT-2 inhibitors in HFrEF: What constitutes best practice today?

Speaker: Professor C. Lam (Singapore, SG)

Access

Implementation in Practice: What are the Practical Considerations?

Speaker: Professor A. Coats (Coventry, GB) Professor C. Lam (Singapore, SG) Professor B. Bozkurt (Houston, US)

Access

Access the full session

A Changing Paradigm: Defining the Future Role of SGLT-2 Inhibitors

Speakers: Professor A. Coats, Professor B. Bozkurt, Professor C. Lam, Professor A. Coats, Professor B. Bozkurt...

Access

Video

About the event

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Congress

Q&A.

About the speakers

Professor Andrew Coats

Professor Biykem Bozkurt

Professor Carolyn Sp Lam

5 more presentations in this session

SGLT-2 Inhibitors in Heart Failure: Where are we now and where are we heading?

Summary of how the Tx paradigm for HF has changed.

Unanswered Questions.

Best practice of SGLT-2 inhibitors in HFrEF: What constitutes best practice today?

Implementation in Practice: What are the Practical Considerations?

Access the full session

A Changing Paradigm: Defining the Future Role of SGLT-2 Inhibitors

About the event

ESC Congress 2021 - The Digital Experience

ESC 365 is supported by